Concurrent Chemo-Radiation Therapy for Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis.
- Author:
Jin Suk KIM
1
;
Kwang Hyub HAN
;
Do Yun LEE
;
Jin Sil SEONG
;
Young Hoon YOUN
;
Jae Youn CHEONG
;
Sang Hoon AHN
;
Chae Yoon CHON
;
Young Myoung MOON
Author Information
1. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
- Publication Type:Original Article ; Clinical Trial ; Controlled Clinical Trial ; English Abstract
- Keywords:
Neoplasm;
Liver;
Hepatocellular carcinoma;
Portal vein thrombosis;
Chemo-radiation therapy;
Cisplatin
- MeSH:
Antineoplastic Agents/*administration & dosage;
Carcinoma, Hepatocellular/complications/radiotherapy/*therapy;
Cisplatin/administration & dosage;
Combined Modality Therapy;
English Abstract;
Female;
Fluorouracil/administration & dosage;
Human;
Infusions, Intra-Arterial;
Liver Neoplasms/complications/radiotherapy/*therapy;
Male;
Middle Aged;
*Portal Vein;
Prognosis;
Venous Thrombosis/*complications
- From:The Korean Journal of Hepatology
2002;8(1):71-79
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: Advanced hepatocellular carcinoma with portal vein thrombosis has a poor prognosis. This study was undertaken to evaluate the therapeutic effects of concurrent chemo-radiation therapy in advanced hepatocellular carcinoma with portal vein thrombosis. METHODS: A total of 54 patients with advanced hepatocellular carcinoma (TNM stage IVa) were enrolled. Nineteen patients were treated with external beam radiotherapy (4,500 cGy/ 5 weeks) and intrahepatic arterial 5-FU infusion (500 mg on 1-5 day and 30-35 day, respectively) via implanted chemoport. The others were treated with intrahepatic arterial cisplatin infusion (80 mg/m2). RESULTS: In patients treated with concurrent chemo-radiation therapy, response rates at 2nd and 6th months were 42.1% and 26.3%, respectively. In patients treated with intrahepatic arterial cisplatin therapy, response rates at 2nd and 6th months were 2.9% and 0%, respectively. The median survival time was 11.6 months in concurrent chemo-radiation therapy and 4.8 months in intrahepatic arterial cisplatin infusion therapy. Concurrent chemo-radiation therapy produced better response rates and longer survival time than those of intrahepatic arterial cisplatin infusion therapy (p<0.05). CONCLUSIONS: Concurrent chemo-radiation therapy achieved favorable results in advanced hepatocellular carcinoma with portal vein thrombosis and can be considered as a treatment option for the management of advanced hepatocellular carcinoma.
